When investors are paying such high price tags for a stock, expectations are high, and any kind of miss can result in a steep ...

We recently compiled a list of the 15 Best Large-Cap Value Stocks to Buy in 2025. In this article, we are going to take a ...

Odyssey Therapeutics is a promising biotech firm poised for IPO success with a focus on inflammatory and autoimmune diseases ...

Biotech and pharma dealmaking is off to a good start in 2025. Meanwhile, digital health fundraising defined by “David and ...

Bank of America Securities analyst Tim Anderson maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) today. The company’s ...

Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas.

We recently published a list of 12 Stocks That Could Split in the Near Future. In this article, we are going to take a look ...

Patent law specialist Hoffmann Eitle is taking over the Dusseldorf office of boutique KSVR (König - Szynka - Tilmann - von Renesse) next month. KSVR partners Gregor König, Dorothea von Renesse and ...

We recently compiled a list of the Jim Cramer Recently Discussed These 17 Stocks And Chinese Hackers. In this article, we are ...

We recently compiled a list of the 9 Stocks on Jim Cramer’s Radar. In this article, we are going to take a look at where Eli ...

All told, Lilly stock still gained 33% in 2024, outperforming the S&P 500 and Nasdaq Composite. Unfortunately, Lilly investors haven't had much to celebrate so far in 2025. On Jan. 14, shares of Lilly ...

New Activin R-based medications can emerge as perfect solutions for balancing weight loss and muscle building, making a ...